Respiratory syncytial virus (RSV) has been reported as a cause of death among autologous peripheral blood stem cell (ASCT) and marrow recipients and recommendations for therapy with aerosolized ribavirin plus intravenous immunoglobulin (IVIG) made. This therapy is expensive, may be toxic, and causes a significant disruption of patient care. The purpose of this study was to evaluate the morbidity and mortality of RSV infections in patients with multiple myeloma undergoing ASCT without ribavirin therapy. 1-3 Respiratory syncytial virus (RSV) is an important community and nosocomial respiratory pathogen for infants, young children and immunocompromised adults.
solized ribavirin and high-dose IVIG has been recently recommended for the treatment of RSV upper respiratory tract infections on the basis of an uncontrolled study from a single center. 6 However, this approach has never been evaluated in randomized trials in adults. The trials in pediatric RSV infections gave conflicting results: some showing clinical improvement, [7] [8] [9] [10] [11] [12] [13] while others showed no benefit [14] [15] [16] [17] [18] or even a detrimental effect (eg prolonged duration of hospitalization, intensive care unit stay, duration of hypoxia, and mechanical ventilation) [19] [20] [21] [22] [23] [24] (Table 1) . A recent metaanalysis of randomized trials concluded that the administration of ribavirin in pediatric RSV infections is not supported by the clinical studies and does not result in decreases in length of hospital stay or mortality rate. 18 More recent studies which included significantly larger numbers of patients than earlier reports, concluded that aerosolized ribavirin was detrimental to infants with RSV infection. [20] [21] [22] 24 Furthermore, aerosolized ribavirin is very expensive, requires special equipment and may be toxic. 19, 25, 26 In addition to therapy with aerosolized ribavirin and IVIG, delay in the treatment of the underlying cancer has been recommended with potential negative effect on the patient's underlying disease.
Because of these concerns and the questionable efficacy of aerosolized ribavirin in non-immunosuppressed children, we evaluated the morbidity and mortality of RSV infections in patients with multiple myeloma undergoing ASCT without ribavirin therapy.
Patients and methods
During the months of February-April 1997, 10 consecutive patients with advanced myeloma underwent ASCT while having active and symptomatic RSV upper respiratory tract infection.
Definitions
An upper respiratory tract infection was defined as the presence of one or more of the following signs/symptoms: rhinorrhea, nasal/sinus congestion, otitis media, pharyngitis or cough with a clear chest exam and chest roentgenogram. Tracheobronchitis was defined as the presence of a deep, persistent cough in association with rhonchi or coarse rales on chest exam and a clear chest roentgenogram. Pneumonia Included patients who tested negative for RSV. Underlying conditions: congenital heart disease, any immunosuppressive disorder, failure to thrive, pulmonary conditions resulting in severe disability, pulmonary conditions of milder disability (eg reactive airway disease, airway obstruction, chronic aspiration). RF = respiratory functions (eg dynamic compliance, total lung resistance)/symptoms (eg cough, crepitations, wheezing, tachypnoea); Imp = improvement; Bronch = bronchiolitis; BPD = bronchopulmonary dysplasia; d = day; h = hour; V = variable and conflicting; CHD = congenital heart disease; LOS = length of hospitalization; LRI = lower respiratory tract infections; NC = no change; O 2 = oxygenation; Shedding = virus shedding; Worse = worsening; -= not reported; (1) = faster clinical improvement; (2) = prolonged hospitalization and ICU stay; (3) = prolonged oxygenation and worsening pulmonary functions; (4) = criticized for using sterile water in placebo; (5) = prolonged hospital length of stay, intensive care and mechanical ventilation; (6) = prolonged hospital length of stay, duration of hypoxia, duration of intensive care unit.
was defined as an acute respiratory disease occurring with a new pulmonary infiltrate. A lymphocyte count Ͻ700/mm 3 and a neutrophil count Ͻ1000/mm 3 were defined as lymphopenia and neutropenia, respectively.
Respiratory specimens consisted of nasopharyngeal washings that have been expelled into a sterile container and transported to the virology laboratory within 2 h on wet ice. Specimens were inoculated into a tube of MRC-5 fibroblasts cells. RSV culture was checked on a daily basis and diagnosed by the characteristic RSV-cytopathic effect and confirmed by staining with a fluorescent-conjugated polyclonal antibody assay. 27, 28 An in vitro enzyme-linked immunosorbent assay (ELISA) membrane test for the rapid and qualitative detection of viral antigen directly (Directigen; Becton Dickinson Microbiology System, Cockeysville, MD, USA) and an immunofluorescence test (IF) (Bartels Diagnostics, Issaquah, WA, USA) were also performed on all specimens.
Hypothetical cost-analysis
We evaluated the cost of delivering therapy had we elected to treat these patients according to the recommendations of Whimbey et al.
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Results
Ten consecutive patients with advanced myeloma had symptomatic RSV infection. Seven patients were males and three were females and their median age was 57 years (range 49 to 65 years). Ten patients had positive results by IF and culture. The ELISA was positive in three of these 10 patients. The underlying myeloma had been previously treated for a median of 15 months (range 3 to 35 months) including high doses of adrenal corticosteroids. Conditioning regimen consisted of high-dose melphalan (200 mg/m 2 ) followed by autologous peripheral stem cell rescue. All patients underwent ASCT while having active RSV infection. Five of these patients became symptomatic and culture positive after undergoing high-dose chemotherapy/ASCT (median, 7 days) while the remaining five underwent ASCT with symptoms and culture-proven RSV infection (median, 4 days before ASCT). All patients became profoundly neutropenic (Ͻ1000 cells/mm 3 ) for a median of 5 days (range 3 to 20 days) and lymphopenic for a median of 20 days (range 8 to 29 days). Aerosolized or intravenous ribavirin was not given to any patient although four patients received high-dose IVIG (Polygam S/D manufactured by Baxter Healthcare, Glendale, CA, USA; distributed by American Red Cross, Washington, DC, USA) at a dose of 1000 mg/kg/day for 3 days. Because of problems with the IVIG supply, one additional patient received only 1 day of IVIG at a lower dose of 400 mg/kg/day.
No patient developed lower respiratory tract infection, required transfer to intensive care unit or died at a median follow-up of 8 months (range 7 to 9 months). One patient developed tracheobronchitis requiring oxygenation by nasal cannula and recovered without ribavirin or IVIG therapy. No delay in the treatment of the underlying myeloma occurred as a result of this approach.
The acquisition cost of 6 g of ribavirin per day is $1498. Assuming that the mean duration of therapy is 11 days, 6 the cost of drug therapy would have been $16 478 per patient, for a total of $164 780. However, the total cost of ribavirin therapy exceeds by far this estimate when the cost of respiratory therapy, equipment, aerosol sampling, hospitalization and other ribavirin-related expenses during hospitalization are added. The precise cost of therapy is difficult to estimate and may vary greatly from one area to another and among healthcare systems.
Discussion
Our results show that patients with multiple myeloma may safely undergo ASCT while having active RSV infection, without any delay in the treatment of the underlying disease or the added inconvenience cost and toxicity of aerosolized ribavirin and IVIG. It is possible, however, that IVIG may have prevented progression to RSV disease among the five patients who received IVIG. That RSV-infected multiple myeloma patients could undergo high-dose cytotoxic therapy without serious morbidity or mortality is remarkable since these patients have deficient production of antibodies, 29 increased dysfunction and catabolism of their normal immunoglobulins, [29] [30] [31] [32] [33] poor response to various antigens including viruses, 34, 35 decreased levels of serum complements, 36 and impaired neutrophil functions. 36, 37 These immune dysfunctions worsen in patients with advanced disease 38, 39 and in the presence of neutropenia. 40, 41 In addition, cell-mediated immunity, was also probably deficient in our patients who had received extensive corticosteroid therapy 42 and were all lymphopenic. Our findings differ from those published by Whimbey et al 6 in a study, in which 16 of 19 patients developed pneumonia. In that report, the mortality rate was 100% in four untreated patients and in three patients in whom therapy was initiated within 24 h of respiratory failure requiring mechanical ventilation, while the response rate to aerosolized ribavirin was reported to be 78% when aerosolized ribavirin was initiated early. These differences can be accounted for by differences in the patient population (two of the patients previously reported had undergone allogeneic transplantation and also different, more toxic conditioning regimens) and the likelihood that at least some of the reported deaths were due to causes other than RSV. More importantly perhaps, our findings of limited RSV infection could be accounted for by less virulent strains than those reported from Houston, as differences in virulence among RSV isolates is well described. 43 On the other hand, several prospective, randomized trials for the treatment of RSV infections in the pediatric patient population have failed to conclusively demonstrate a significant clinical benefit when mortality rate, respiratory deterioration and duration of hospital stay were evaluated. 18 According to 91% of 113 surveyed pediatric critical care physicians in the United States, the literature does not support the previous recommendation by the American Academy of Pediatrics for the use of ribavirin in children with RSV. 44 These physicians expressed concern that this recommendation could put them at risk of malpractice litigation should they choose not to use ribavirin. Since then, these recommendations for the use of ribavirin have been changed from 'should be used' 45 to 'may be considered'. 46 We submit that, like in children, aerosolized ribavirin is of limited usefulness in adult transplant recipients for the following reasons: (1) The most recent and larger trials (including 2206 patients) of the treatment of RSV infections in infants concluded that aerosolized ribavirin was detrimental because of prolonged hospitalization, ICU stay or prolonged oxygenation and worsening pulmonary functions in those patients who received ribavirin. [20] [21] [22] 24 By contrast, the trials that support the use of ribavirin included a very small number of patients (a total of 188 patients) [7] [8] [9] [10] [11] [12] or used water installation in the placebo arm. 13 It is important to stress, however, that the above-mentioned trials were also conducted in pediatric patients. (2) Ribavirin does not prevent breakthrough (fatal) RSV pneumonia. (6) Finally, the prohibitive cost of ribavirin in the face of its unproven role in adults with hematological cancer may be an impediment to its routine use.
The recommendation to use IVIG in RSV infections is not based on clinical data since immunoglobulin therapy (even with specific RSV Ig) has been shown to be ineffective against established RSV infection in humans. 52, 53 In conclusion, our pilot study suggests that multiple myeloma patients may safely undergo ASCT despite ongoing RSV infection without aerosolized ribavirin or delaying therapy for the underlying disease. It is possible however, that IVIG may have had some antiviral activity among the five patients who received it. Controlled studies are thus urgently needed to define the optimal management of RSV infections in autologous transplant recipients. Until the conclusion of such studies, aerosolized ribavirin plus IVIG for RSV upper respiratory tract infections should be considered experimental.
